Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring.

Antiviral therapy - 1 Jan 2017

Simonetti Francesco R, Cattaneo Dario, Zanchetta Nadia, Giacomet Vania, Micheli Valeria, Ciminera Nadia, Gervasoni Cristina

Abstract excerpt

Here we describe a case of an HIV-infected young woman with extensive drug-resistant virus, who was successfully switched from a raltegravir-based regimen to a dolutegravir-based intensified antiretroviral regimen a few days before scheduled caesarean section because of the still detectable viral load. The trough concentrations of all antiretroviral drugs before and after delivery are also described. Our case...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Availability
Share to Cesarean Section

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Drug Substitution

Share to Heterocyclic Compounds, 3-Ring

Share to Oxazines

Share to Pyridones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 28051809
DOI: 10.3851/IMP3122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring.PMID 28051809Read ↗

Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancySemantic proximity Read ↗

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIVSemantic proximity Read ↗

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.Semantic proximity Read ↗

An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomicsSemantic proximity Read ↗

Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort studySemantic proximity Read ↗

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Semantic proximity Read ↗

[Maternal and neonatal drug resistance].Semantic proximity Read ↗

Pharmacogenetics of efavirenz exposure in cervicovaginal fluid during pregnancy and postpartumSemantic proximity Read ↗

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.Semantic proximity Read ↗

Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.Semantic proximity Read ↗

Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission.Semantic proximity Read ↗

Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.